Resecurity to Exhibit at GISEC Global 2025 in Strategic Partnership with EMT Distribution
LOS ANGELES--(BUSINESS WIRE)-- Resecurity, a leading provider of advanced cybersecurity solutions, is pleased to announce its participation in GISEC Global 2025, the largest and most impactful cybersecurity exhibition in the Middle East and Africa. The event will take place from , at the Dubai World Trade Centre.
This year, Resecurity will exhibit alongside EMT Distribution, a premier value-added distributor and Gold Sponsor of GISEC Global 2025. Together, the two companies will present their latest cybersecurity innovations and joint initiatives to strengthen digital defense across government, enterprise, and critical infrastructure sectors.
GISEC Global serves as a central hub for cybersecurity innovation, collaboration, and knowledge exchange. It is expected to attract over 750 exhibiting brands and more than 25,000 professionals from 160 countries. The event brings together global industry leaders, national cybersecurity agencies, and solution providers to address the most pressing cyber threats facing the region and the world.
At the event, Resecurity will showcase its most recent advancements in:
Cyber Threat Intelligence
Digital Risk Monitoring
Brand and Identity Protection
Real-Time Fraud Prevention
These solutions are designed to help organizations detect, analyze, and respond to cyber threats proactively. They support risk mitigation, regulatory compliance, and operational resilience.
As part of a featured experience at GISEC, Resecurity and EMT Distribution will participate in the Cyber Escape Room, a collaborative initiative launched with the UAE Cyber Security Council and Dubai World Trade Centre. This immersive and gamified activity simulates real-world cyberattack scenarios, allowing participants to test their detection and response capabilities in a controlled environment.
'We are excited to return to GISEC Global and collaborate with EMT Distribution to showcase our latest cybersecurity solutions,' said Ahmad Halabi, Managing Director of Resecurity (MENA). 'Our joint efforts aim to provide attendees with valuable insights and practical experiences that highlight the importance of proactive cybersecurity strategies.'
'Cybersecurity has become a national priority in the region. At EMT, we are proud to partner with Resecurity to bring forward-thinking solutions and educational experiences like the Cyber Escape Room to GISEC,' said Mo Mobasseri, CEO of EMT Distribution. 'We believe this collaboration will empower attendees to better understand the threat landscape and prepare for what's ahead.'
Visitors are invited to meet the Resecurity and EMT Distribution teams at Stand B145 to explore their cybersecurity offerings and experience the Cyber Escape Room firsthand.
About Resecurity
Resecurity® is a cybersecurity company that delivers a unified endpoint protection, fraud prevention, risk management, and cyber threat intelligence platform. Known for providing best-of-breed data-driven intelligence solutions, Resecurity's services and platforms focus on early-warning identification of data breaches and comprehensive protection against cybersecurity risks. Founded in 2016, it has been globally recognized as one of the world's most innovative cybersecurity companies with the sole mission of enabling organizations to combat cyber threats regardless of how sophisticated they are. Most recently, by Inc. Magazine, Resecurity was named one of the Top 10 fastest-growing private cybersecurity companies in Los Angeles, California. As a member of InfraGard National Members Alliance (INMA), AFCEA, NDIA, SIA, FS-ISAC, and the American Chamber of Commerce in Saudi Arabia (AmChamKSA), Singapore (AmChamSG), Korea (AmChamKorea), Mexico (AmChamMX), Thailand (AmChamThailand), and UAE (AmChamDubai). To learn more about Resecurity, visit https://resecurity.com.
About EMT Distribution
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
an hour ago
- Forbes
Is Employee Loyalty Really Dead?
Is Employee Loyalty Dead? getty In an era where switching jobs every couple of years (or months) feels normal, people often ask what can be done to reverse this trend. Here are some key considerations to keep in mind when seeking to engage and retain staff. Employee loyalty is about people giving their all while employed by you. It's better to have a fully engaged employee who is loyal for a brief period than an employee who has one foot out the door all the time. Employees are free agents and will go wherever they get the best deal and where they're treated well. If you want people to stay, make sure you give them something tough to find elsewhere—outstanding leadership. Be sure to pay competitive wages, even if you have the upper hand, as the pendulum could change at a moment's notice. When staffing positions, be less concerned with longevity and focus on the value a prospective employee will bring to your team. Keep in mind that many great people have lost their jobs recently due to circumstances beyond their control. This means you have an excellent opportunity to pick up talent that may not have been an option years prior. Hiring the right people from the start is the best way to reduce turnover. Don't assume your hiring manager knows how to hire, as very few leaders have been properly trained in assessing candidates. Make employee selection training a requirement for all managers and watch the quality of your hires rise while employee turnover plummets. People don't work for companies. They work for people, which is why you should be very careful whom you let into management. Make sure the people you're placing into supervisory and management roles are worthy of these positions. If they're not, you're at risk of losing great employees, which in the end will cost your company its reputation and a lot of money. The best way to cultivate employee loyalty is to treat people the way you'd like to be treated. Provide employees with the opportunity to grow where they're planted. Nurture your relationships with your team and watch them flourish. When employees speak, listen deeply and act. Don't wait until the annual employee engagement survey to come around again before fixing problems you know exist. Employee engagement and loyalty do not have to be a thing of the past if you're willing to work on a meaningful future with those in your employ. In the end, people remember how you made them feel, which will determine whether they remain loyal to you or go to your competitor.
Yahoo
an hour ago
- Yahoo
Can Spotify Stock Hit $900 in 2025?
Valued at a market capitalization of $145 billion, Spotify (SPOT) offers audio streaming services worldwide. The tech stock went public in early 2018 and has since returned close to 400% to shareholders. Earlier this week, Pivotal Research raised Spotify's price target to a Wall Street-high of $900 (from $800), maintaining a 'Buy' rating and citing the company's dominant position in the premium audio streaming market. Robotaxis, Powell and Other Key Things to Watch this Week Make Over a 2.4% One-Month Yield Shorting Nvidia Out-of-the-Money Puts Is Quantum Computing (QUBT) Stock a Buy on This Bold Technological Breakthrough? Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! The investment firm expects Spotify to reach 1 billion monthly active users from its current base of 700 million, projecting a 60% five-year compound annual growth rate in EBITDA, driven by pricing power, subscriber growth, and advertising expansion. Analysts highlighted Spotify's under-monetized advertising business and expansion opportunities beyond music into video, social features, and live programming. The valuation assumes a $175 billion enterprise value using discounted cash flow analysis with a 16x terminal EBITDA multiple for 2030. Let's see if you should buy SPOT stock at the current price. Spotify Technology reported robust Q1 results, demonstrating resilience amid global economic uncertainty. The audio streaming giant added 5 million net premium subscribers, reaching a total of 268 million subscribers, indicating 12% year-over-year growth and marking the second-highest Q1 subscriber addition in the company's history. Total revenue reached 4.2 billion euros, representing a 15% year-over-year increase on a constant currency basis, while premium revenue increased by 16%. Its advertising business showed encouraging momentum with 5% currency-neutral growth, benefiting from new automated features and programmatic tools that expanded advertiser participation from thousands to tens of thousands of active clients. CEO Daniel Ek emphasized 2025 as 'the year of accelerated execution,' highlighting significant operational improvements. Spotify's video podcast monetization strategy gained substantial traction through the Spotify Partner Program, which paid out over $100 million to creators in the first quarter alone. Video content engagement surged 44% year-over-year, with Gen Z users spending 81% more time consuming video content, demonstrating the format's appeal to younger demographics. Spotify's AI-first approach continues to yield results, with the AI Playlist now available in over 40 markets, enabling users to interact with the platform in natural language. These technological investments support Spotify's core strategy of maximizing user engagement and retention while expanding monetization opportunities. Emerging markets drove two-thirds of subscriber outperformance, with Latin America and Asia Pacific showing strong growth. This geographic diversification, combined with Spotify's flexible freemium model, positions the platform well during uncertain economic periods. Gross margin expanded 400 basis points year-over-year to 31.6%, while operating income reached 225 million euros. The company maintains a strong balance sheet with 8 billion euros in cash and short-term investments, providing substantial flexibility for continued investment in innovation. Looking ahead, Spotify expects Q2 revenue of 4.3 billion euros with 689 million monthly active users and 273 million subscribers. Management remains confident in long-term growth prospects, with Ek suggesting the potential for reaching 1 billion subscribers, emphasizing that consistent problem-solving and value creation will drive sustainable expansion in the global audio entertainment market. Analysts tracking Spotify stock expect revenue to increase from $16.3 billion in 2024 to $33 billion in 2029. During this period, adjusted earnings per share are expected to grow from $5.71 to $21.23. Moreover, free cash flow is forecast to improve from $2.37 billion in 2024 to $7.34 billion in 2029. If SPOT stock is priced at 40 times forward free cash flow (FCF), it could double over the next four years. Out of the 32 analysts covering SPOT stock, 19 recommend 'Strong Buy,' two recommend 'Moderate Buy,' nine recommend 'Hold,' one recommends 'Moderate Sell,' and one recommends 'Strong Sell.' The average target price for Spotify stock is $687, 3% below its current price. On the date of publication, Aditya Raghunath did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Business Wire
an hour ago
- Business Wire
Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, announced today that it will present data from its Phase 3 SAPPHIRE clinical trial (NCT05156320) in an oral presentation at Cure SMA's Annual SMA Research & Clinical Care Meeting being held June 25-27, 2025, in Anaheim, California. SAPPHIRE evaluated the safety and efficacy of apitegromab, an investigational muscle-targeted treatment that is being developed to provide clinically meaningful improvement in motor function for people living with SMA who are receiving SMN-targeted treatments. Scholar Rock previously shared positive topline data from the trial in October 2024 and announced in March 2025 that the U.S. FDA accepted its BLA for apitegromab. The application has a priority review designation, and the FDA has assigned a PDUFA target action date of September 22, 2025. Details of the oral presentation are as follows: Title: Efficacy and Safety of Apitegromab in Individuals with Type 2 and Type 3 Spinal Muscular Atrophy Evaluated in the Phase 3 SAPPHIRE Trial Presentation type: Oral presentation Presenter: Basil T. Darras, M.D., Associate Neurologist-in-Chief, Boston Children's Hospital and Professor of Neurology, Harvard Medical School Location: Sequoia Ballroom, Disney's Grand Californian Hotel Date and time: Friday, June 27, 11:20 a.m. PDT Scholar Rock will also present a poster on a systematic literature review of characterization of the longer-term effectiveness of SMN-targeted therapies for SMA. The details of that poster presentation are as follows: Title: Characterization of the Longer-Term Effectiveness of SMN-Targeted Treatments for Spinal Muscular Atrophy: A Systematic Literature Review Presentation type: Poster presentation Presenter: Jena M. Krueger, M.D., Helen DeVos Children's Hospital Grand Rapids, Michigan Location: Frontier Tower Magic Kingdom Rooms 2 & 3, Disneyland Hotel Date and time: Wednesday, June 25, 4:30-6:30 p.m. PDT The presentations will be made available in the Publications & Posters section of Scholar Rock's website following the conference. For conference information, visit About Apitegromab Apitegromab is an investigational fully human monoclonal antibody inhibiting myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. It is the first muscle-targeted treatment candidate in spinal muscular atrophy (SMA) to demonstrate clinical success in a pivotal phase 3 clinical trial. Additionally, in the EMBRAZE Phase 2 proof-of-concept trial in obesity, patients receiving apitegromab dosed at 10mg/kg with tirzepatide over 24 weeks showed a statistically significant preservation of lean mass relative to tirzepatide alone. Myostatin, a member of the TGFβ superfamily of growth factors, is expressed primarily by skeletal muscle cells, and the absence of its gene is associated with an increase in muscle mass and strength in multiple animal species, including humans. Scholar Rock believes that its highly selective targeting of pro- and latent forms of myostatin with apitegromab may lead to a clinically meaningful improvement in motor function in patients with SMA. The U.S. Food and Drug Administration (FDA) has granted Fast Track, Orphan Drug and Rare Pediatric Disease designations, and the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Orphan Medicinal Product designations, to apitegromab for the treatment of SMA. Apitegromab has not been approved for any use by the FDA or any other regulatory agency. About the Phase 3 SAPPHIRE Trial SAPPHIRE was a randomized, double-blind, placebo-controlled Phase 3 clinical trial that evaluated the safety and efficacy of apitegromab in nonambulatory patients with Types 2 and 3 SMA who were receiving current standard of care (either nusinersen or risdiplam). SAPPHIRE enrolled 156 patients aged 2-12 years old in the main efficacy population. These patients were randomized 1:1:1 to receive either apitegromab 10 mg/kg, apitegromab 20 mg/kg, or placebo by intravenous (IV) infusion every 4 weeks for 12 months. An exploratory population including 32 patients aged 13-21 years old was also evaluated. These patients were randomized 2:1 to receive either apitegromab 20 mg/kg or placebo every 4 weeks for 12 months. The SAPPHIRE trial met its primary endpoint for the main efficacy population with a statistically significant 1.8-point improvement (p=0.0192) based on apitegromab combined dose (10 mg/kg and 20 mg/kg) and standard of care (SOC) versus placebo and SOC as measured by the Hammersmith Functional Motor Scale-Expanded at week 52 (additional details in the topline data release). About SMA Spinal muscular atrophy (SMA) is a rare, genetic neuromuscular disease that afflicts an estimated 30,000 to 35,000 people in the United States and Europe. The disease is characterized by the loss of motor neurons, atrophy of the voluntary muscles of the limbs and trunk, and progressive muscle weakness. While there has been progress in the development of therapeutics that address the loss of motor neurons, there continues to be a high unmet need for therapies that directly address the progressive muscle weakness that leads to loss of motor function in SMA. About Scholar Rock Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily, the company is named for the visual resemblance of a scholar rock to protein structures. Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at and follow @ScholarRock and on LinkedIn. Availability of Other Information About Scholar Rock Investors and others should note that we communicate with our investors and the public using our company website including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website or on X (formerly known as Twitter) or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock's future expectations, plans and prospects, including without limitation, Scholar Rock's expectations regarding its growth, strategy, progress and plans for apitegromab. The use of words such as 'may,' 'might,' 'could,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'project,' 'intend,' 'future,' 'potential,' or 'continue,' and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation, whether the results from the Phase 3 clinical trial of apitegromab, are not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidates, and may not be sufficient for regulatory approval; Scholar Rock's ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline; the data generated from Scholar Rock's nonclinical studies and clinical trials; information provided or decisions made by regulatory authorities; competition from third parties that are developing products for similar uses; Scholar Rock's ability to obtain, maintain and protect its intellectual property; Scholar Rock's dependence on third parties for development and manufacture of product candidates including, without limitation, supply for apitegromab; and Scholar Rock's ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances; its ability to obtain regulatory approval of apitegromab; and the anticipated commercial launch in the United States of apitegromab in the fourth quarter of 2025 and new business initiatives; as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock's subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock's views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law.
